
Federica Martorana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9610350/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treatment Reviews, 2018, 68, 102-110.	7.7	183
2	AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?. Frontiers in Pharmacology, 2021, 12, 662232.	3.5	109
3	Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. Genes, 2019, 10, 709.	2.4	71
4	Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment. International Journal of Molecular Sciences, 2019, 20, 3258.	4.1	38
5	Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery. Nature Communications, 2021, 12, 5006.	12.8	38
6	Biomarkers and prognostic factors for malignant pleural mesothelioma. Future Oncology, 2015, 11, 29-33.	2.4	23
7	Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma. Frontiers in Oncology, 2020, 10, 612385.	2.8	23
8	PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance. Critical Reviews in Oncology/Hematology, 2021, 162, 103334.	4.4	20
9	Radiomics in cervical and endometrial cancer. British Journal of Radiology, 2021, 94, 20201314.	2.2	19
10	Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer. International Journal of Molecular Sciences, 2021, 22, 7707.	4.1	16
11	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. Cancers, 2022, 14, 953.	3.7	16
12	A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors. Molecules, 2021, 26, 7294.	3.8	12
13	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. Critical Reviews in Oncology/Hematology, 2021, 168, 103539.	4.4	11
14	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5012-5019.	7.0	10
15	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. Cancer Treatment Reviews, 2021, 101, 102300.	7.7	8
16	Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. Expert Review of Anticancer Therapy, 2022, 22, 343-351.	2.4	6
17	Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily. Cancer Management and Research, 2022, Volume 14, 1341-1352.	1.9	5
18	Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience. Pathology Research and Practice, 2022, 232, 153820.	2.3	4

Federica Martorana

#	Article	IF	CITATIONS
19	Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma. Future Oncology, 2020, 16, 9-13.	2.4	3
20	Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases. Case Reports in Oncological Medicine, 2021, 2021, 1-5.	0.3	2
21	The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities. Translational Oncology, 2021, 14, 101104.	3.7	2
22	A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic. Diagnostics, 2021, 11, 1502.	2.6	1
23	Efficacy of mitomycin C plus a fluoropyrimidine in pretreated patients with metastatic colorectal cancer eligible to regorafenib: Results of a retrospective study Journal of Clinical Oncology, 2015, 33, e14661-e14661.	1.6	1
24	Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study. AIMS Medical Science, 2017, 4, 456-464.	0.4	1
25	Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study Journal of Clinical Oncology, 2018, 36, e12629-e12629.	1.6	0